Krka d. d Total Assets
Krka d. d total assets. Based on the latest financial reports, Krka d. d (KRK) holds total assets worth zł3.34 Billion PLN (≈ $918.05 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Krka d. d (KRK) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Krka d. d (2010–2025)
Total assets of Krka d. d from 2010 to 2025. This chart illustrates how Krka d. d's total assets have evolved over time, based on quarterly financial data. See Krka d. d stock price for real-time trading data and today's change.
Krka d. d - Asset Composition Analysis
Krka d. d Total Assets Breakdown (December 2025)
Krka d. d total assets breakdown as of December 2025. Krka d. d's total assets of zł3.34 Billion consist of 65.2% current assets and 34.8% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 11.4% |
| Accounts Receivable | zł734.05 Million | 24.1% |
| Inventory | zł644.42 Million | 21.2% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł57.14 Million | 1.9% |
| Goodwill | zł42.64 Million | 1.4% |
Asset Composition Trend (2010–2025)
This chart illustrates how Krka d. d's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore KRK working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Krka d. d's current assets represent 65.2% of total assets in 2025, an increase from 43.1% in 2010.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2025, up from 0.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 27.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 24.1% of total assets.
Krka d. d Competitors by Total Assets
Key competitors of Krka d. d based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Krka d. d - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.21 | 4.42 | 4.24 |
| Quick Ratio | 3.03 | 3.13 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł1.71 Billion | zł1.62 Billion | zł1.04 Billion |
Krka d. d - Advanced Valuation Insights
This section examines the relationship between Krka d. d's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.03 |
| Latest Market Cap to Assets Ratio | 3.03 |
| Asset Growth Rate (YoY) | 6.8% |
| Total Assets | zł3.04 Billion |
| Market Capitalization | $9.23 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Krka d. d's assets at a significant premium (3.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Krka d. d's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Krka d. d (2010–2025)
The table below shows the annual total assets of Krka d. d from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł3.04 Billion ≈ $837.79 Million |
+6.85% |
| 2024-12-31 | zł2.85 Billion ≈ $784.09 Million |
+3.07% |
| 2023-12-31 | zł2.76 Billion ≈ $760.77 Million |
+2.86% |
| 2022-12-31 | zł2.69 Billion ≈ $739.64 Million |
+5.90% |
| 2021-12-31 | zł2.54 Billion ≈ $698.41 Million |
+13.52% |
| 2020-12-31 | zł2.24 Billion ≈ $615.25 Million |
+2.33% |
| 2019-12-31 | zł2.18 Billion ≈ $601.24 Million |
+10.05% |
| 2018-12-31 | zł1.99 Billion ≈ $546.32 Million |
+3.44% |
| 2017-12-31 | zł1.92 Billion ≈ $528.17 Million |
+0.40% |
| 2016-12-31 | zł1.91 Billion ≈ $526.08 Million |
+5.66% |
| 2015-12-31 | zł1.81 Billion ≈ $497.92 Million |
+0.75% |
| 2014-12-31 | zł1.80 Billion ≈ $494.21 Million |
+2.04% |
| 2013-12-31 | zł1.76 Billion ≈ $484.35 Million |
+8.18% |
| 2012-12-31 | zł1.63 Billion ≈ $447.70 Million |
+6.04% |
| 2011-12-31 | zł1.53 Billion ≈ $422.19 Million |
+3.08% |
| 2010-12-31 | zł1.49 Billion ≈ $409.58 Million |
-- |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more